A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

NCT07465653 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: HJB647 low dose
DRUG: HJB647 high dose
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals